You are here

New treatments

Avastin and other therapies

Many of the targeted therapies such as avastin, recently developed, can have a role in the management of patient's cancers, and for some but not all individuals these treatments may be appropriate. Public healthcare systems around the world have to prioritise by providing best care to the "average" patient in a one-size-fits-all way generally, and this may makes it difficult to access personalised care where it is needed. We offer excellence of care that is focussed on the individual, not the "average" patient. Thus at the QASMC patients will receive the best treatment independent of where they live or how a public healthcare system views its priorities.

It is also possible to use biomarkers to select and potentially monitor these targeted treatments. Biomarkers provide unique clues about each patient’s cancer, and where these biomarkers are properly validated - which treatments are more likely to be effective, and just as importantly, which therapies are more likely to fail.

Why we use biomarker profiles in planning each complex patient’s case-management.

Latest validated treatments implemented with minimum delay

QASMC pioneers new treatment for cancers that are resistant to conventional treatment.

In particular we have focussed interests in managing disease that has spread into the abdominal space which is a difficult situation to manage. This can produce pain, abdominal distension and discomfort, large build-up of fluid (called ascites) or bowel obstruction. For example we are able to offer surgery where appropriate to control bowel obstruction or remove the cancer, or drugs such as Removab when indicated to target ascites, or indeed ways of draining the abdominal fluid that are not generally available (see below).

Illustration shows how spread of a tumour causes malignant ascites:

Alfapump (

QASMC is able to offer the Alfapump, a novel treatment for ascites (build-up of fluid in the abdomen) which is a common complication of cancer that has spread into the abdomen including ovarian, bowel and liver, uterus and breast cancers.

This pump is the size of an iPod and is implanted under the skin in a small operation. The outflow of the pump is into the bladder so that ascites fluid is pumped from the abdomen and into the bladder which is emptied naturally. The pump is intended to bring great relief to patients who hitherto undergo frequent and painful fluid removal via a needle cannula, and at QASMC we are early adopters of this novel technology.